More misery for Merck & Co as Keytruda combo suffers setback

30 October 2017
2019_biotech_test_vial_discovery_big

US pharma giant Merck & Co (NYSE: MRK) is having a ghastly Halloween season.

On Friday, its shares closed 6% down after the  company presented financial results for the latest quarter that included confirmation of increasing competition, a costly cyber attack and further expenses that hit revenue and earnings.

Another reason for the share slipping late on Friday – and the likely cause of its further 5% drop by Monday lunchtime to $55.43, was news that Merck had withdrawn its European application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology